Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
38.87+0.04 (+0.10%)
At close: 4:00PM EDT
38.87 0.00 (0.00%)
After hours: 04:32PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close38.83
Open38.92
Bid38.10 x 800
Ask39.45 x 1200
Day's Range38.24 - 39.18
52 Week Range27.21 - 56.40
Volume451,972
Avg. Volume762,596
Market Cap5.533B
Beta (5Y Monthly)1.44
PE Ratio (TTM)24.77
EPS (TTM)1.57
Earnings DateNov 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.05
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
-3% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for HALO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Halozyme Therapeutics, Inc.
    HALO: Lowering target price to $39.00HALOZYME THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $39.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    11 days agoArgus Research
View more
  • PR Newswire

    Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call

    Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2021 on November 2 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the third quarter ended September 30, 2021, following the close of trading.

  • Benzinga

    Notable Halozyme Therapeutics Insider Trades $2.7M In Company Stock

    Helen Torley, President And CEO at Halozyme Therapeutics (NASDAQ:HALO), made a large buy and sell of company shares on October 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Helen Torley exercised options to purchase 50,000 Halozyme Therapeutics shares at a price of $14.66 per share for a total of $733,000 on October 4. They then sold their shares on the same day in the open market. They sold at prices ranging from $3

  • Benzinga

    Notable Halozyme Therapeutics Insider Trades $1.6M In Company Stock

    Michael J Labarre, SVP And Chief Technical Officer at Halozyme Therapeutics (NASDAQ:HALO), made a large buy and sell of company shares on October 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Michael J Labarre exercised options to purchase 29,450 Halozyme Therapeutics shares at a price of $13.10 per share for a total of $385,795 on October 1. They then sold their shares on the same day in the open market. They sold a

Advertisement
Advertisement